The purpose of the current study is to design and synthesis of novel Mn2+ complex as an alternative to well-established Gd3+ chelates for use as a liver-targeting MR imaging agent. This new complex exhibits high R1 relaxivity (2.3 mM−1 s−1) than clinically approved Mn-DPDP® (1.6 mM−1 s−1) at 1.5 T. It is also kinetically much inert than that of Magnevist®. In vivo MRI enhancement pattern compares well with those of liver-specific MRI CAs such as Primovist® and Multihance®. It shows greater tumor detection in a liver tumor model with negligible toxicity in a clinical dose.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords